Watch FedEx, BlackBerry, and Nike This Week
Investors have several companies to watch this week that are posting quarterly earnings reports.Ahead of its report scheduled for Tuesday, FedEx (FDX) announced a dividend of $1.45 a share on June 9. It increased the rate by 5.1% for a forward yield of 2.56%. Investors do not expect the parcel delivery supplier to report strong results. FDX stock is in a downtrend, peaking at $313.84 in the last year.Canada’s BlackBerry (BB) will post first-quarter earnings. In the last quarter, the firm issued a weak sales outlook of between $107 million and $115 million. Tariffs are an indirect reason for the shortfall. Still, the company’s primary business is technology solutions in the automotive market. QNX sales might exceed expectations.Nike (NKE) shares are in a steep downtrend over the last year, ahead of the earnings report. The company is reportedly delaying a new sub-brand. Nike originally planned to launch a Kim Kardashian brand in the spring. Instead, it might launch the NikeSims product line sometime this year.Nike is struggling with weak store and online sales. Its product prices are too high. In addition, it did not offer its customers anything new.Last quarter, Nike posted a negative 7% growth rate. Shares trade at a forward P/E of 28.03 times. This is a premium for a firm whose business is not showing signs of a turnaround.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


